Amgen

Amgen Secures FDA Approval for Uplizna, Paving the Way for Enhanced Treatment of Rare Disease

2 days ago

In a significant development in the biopharmaceutical sector, Amgen has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its innovative drug, Uplizna, aimed at treating a rare and often debilitating disease. This approval marks a critical advancement not only for Amgen but also for patients suffering from this condition, which has been challenging to manage with existing therapies.

Amgen Advances Toward Obesity Treatment Breakthrough with Final Stage Studies

1 month ago

In a significant move within the pharmaceutical industry, Amgen has initiated the final phase of clinical trials for its innovative obesity drug, which is set to be administered on a monthly basis. This development marks a crucial step forward in the company's efforts to penetrate the lucrative obesity treatment market, an area that has seen increased focus due to the alarming rise in obesity rates globally.

Amgen Reports Strong Growth Projections, But Faces Setback With Obesity Drug

2 months ago

In a recent announcement, Amgen, one of the prominent players in the biopharmaceutical industry, revealed its optimistic outlook for future growth, surpassing the expectations set by analysts. The company attributes this positive trajectory largely to its diverse portfolio of drugs aimed at various health conditions. However, amidst this encouraging news, Amgen is simultaneously confronting a significant challenge: the ongoing pauses in the development of its obesity drug, which has created a cloud of uncertainty over its market potential.

Breakthrough Weight Loss Treatment: Amgen's Latest Drug Leads to 20% Reduction in Body Weight in New Study

4 months ago

In a groundbreaking development in the field of obesity treatment, a recent study has demonstrated that an experimental drug from Amgen has the potential to help patients lose up to 20% of their body weight over the course of a year. This remarkable achievement could significantly change the landscape for obesity management, offering hope to millions of individuals struggling with weight-related health issues.

Amgen Reports Stronger-Than-Expected Profit Amid Lower Costs

5 months ago

Biotechnology giant Amgen has recently announced robust quarterly earnings that exceeded analysts' expectations, primarily driven by lower-than-anticipated production costs. The company's financial performance showcases its ability to navigate through challenging economic conditions while maintaining profitability.